4//SEC Filing
Anacor Pharmaceuticals, Inc. 4
Accession 0001209191-16-096112
CIK 0001411158operating
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 7:06 PM ET
Size
14.0 KB
Accession
0001209191-16-096112
Insider Transaction Report
Form 4
Zane Lee
VP, Clinical Dev & Interim CMO
Transactions
- Award
Common Stock
2016-02-03+4,375→ 44,044 total - Award
Stock Option (right to buy)
2016-02-03+22,136→ 22,136 totalExercise: $78.91Exp: 2026-02-03→ Common Stock (22,136 underlying) - Award
Performance Restricted Stock Units
2016-02-03+4,375→ 4,375 total→ Common Stock (4,375 underlying)
Footnotes (4)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2016.
- [F2]Includes shares purchased in 2016 pursuant to the Issuer's ESPP.
- [F3]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date is January 1, 2016.
- [F4]Represents performance restricted stock units granted to the Reporting Person. Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and will vest, if at all, based on the achievement of certain specified performance goals.
Issuer
Anacor Pharmaceuticals, Inc.
CIK 0001411158
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001411158
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 7:06 PM ET
- Size
- 14.0 KB